Follow
Edwin Bremer, prof. dr.
Edwin Bremer, prof. dr.
University Medical Center Groningen/Dept. of Hematology
Verified email at umcg.nl
Title
Cited by
Cited by
Year
The role of macrophages in cancer development and therapy
E Cendrowicz, Z Sas, E Bremer, TP Rygiel
Cancers 13 (08), 1946, 2021
1742021
The multifaceted role of autophagy in cancer and the microenvironment
H Folkerts, S Hilgendorf, E Vellenga, E Bremer, VR Wiersma
Medicinal research reviews 39 (2), 517-560, 2019
1692019
Targeted induction of apoptosis for cancer therapy: current progress and prospects
E Bremer, G Van Dam, BJ Kroesen, L de Leij, W Helfrich
Trends in molecular medicine 12 (8), 382-393, 2006
1692006
Therapeutic potential of Galectin‐9 in human disease
VR Wiersma, M de Bruyn, W Helfrich, E Bremer
Medicinal research reviews 33 (S1), E102-E126, 2013
1632013
Mechanisms of translocation of ER chaperones to the cell surface and immunomodulatory roles in cancer and autoimmunity
VR Wiersma, M Michalak, TM Abdullah, E Bremer, P Eggleton
Frontiers in oncology 5, 7, 2015
1612015
Carbon monoxide-releasing molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats
Y Wei, P Chen, M de Bruyn, W Zhang, E Bremer, W Helfrich
BMC gastroenterology 10, 1-9, 2010
1372010
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy
E Bremer
International Scholarly Research Notices 2013, 2013
1342013
Target cell‐restricted and‐enhanced apoptosis induction by a scFv: sTRAIL fusion protein with specificity for the pancarcinoma‐associated antigen EGP2
E Bremer, J Kuijlen, D Samplonius, H Walczak, L de Leij, W Helfrich
International journal of cancer 109 (2), 281-290, 2004
1292004
Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor …
E Bremer, DF Samplonius, L van Genne, MH Dijkstra, BJ Kroesen, ...
Journal of Biological Chemistry 280 (11), 10025-10033, 2005
1262005
Target cell–restricted apoptosis induction of acute leukemic t cells by a recombinant tumor necrosis factor–related apoptosis-inducing ligand fusion protein with specificity …
E Bremer, DF Samplonius, M Peipp, L van Genne, BJ Kroesen, GH Fey, ...
Cancer research 65 (8), 3380-3388, 2005
1082005
Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: results of a phase II clinical trial
S Wang, Y Lin, X Xiong, L Wang, Y Guo, Y Chen, S Chen, G Wang, P Lin, ...
Clinical Cancer Research 26 (18), 4921-4932, 2020
1022020
Antibody-based fusion proteins to target death receptors in cancer
M de Bruyn, E Bremer, W Helfrich
Cancer letters 332 (2), 175-183, 2013
942013
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
M de Bruyn, AA Rybczynska, Y Wei, M Schwenkert, GH Fey, ...
Molecular cancer 9, 1-14, 2010
852010
on TRAIL for malignant glioma therapy?
JMA Kuijlen, E Bremer, JJA Mooij, WFA Den Dunnen, W Helfrich
Neuropathology and applied neurobiology 36 (3), 168-182, 2010
852010
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability
B Ten Cate, E Bremer, M De Bruyn, T Bijma, D Samplonius, ...
Leukemia 23 (8), 1389-1397, 2009
842009
CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy
FL Komdeur, MCA Wouters, HH Workel, AM Tijans, ALJ Terwindt, ...
Oncotarget 7 (46), 75130, 2016
792016
Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein
J Stieglmaier, E Bremer, C Kellner, TM Liebig, B Ten Cate, M Peipp, ...
Cancer Immunology, Immunotherapy 57, 233-246, 2008
792008
Exceptionally potent anti-tumor bystander activity of an scFv: sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells
E Bremer, D Samplonius, BJ Kroesen, L van Genne, L de Leij, W Helfrich
Neoplasia 6 (5), 636-645, 2004
742004
Calreticulin, a therapeutic target?
P Eggleton, E Bremer, E Dudek, M Michalak
Expert Opinion on Therapeutic Targets 20 (9), 1137-1147, 2016
732016
CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
PE Van Bommel, Y He, I Schepel, MAJM Hendriks, VR Wiersma, ...
Oncoimmunology 7 (2), e1386361, 2018
712018
The system can't perform the operation now. Try again later.
Articles 1–20